Jupipac 260 Injection
Marketer
Jupiter Formulations Private Limited
Salt Composition
Paclitaxel (6mg/ml)
Overview Jupipac 260 Injection
Oncaspar 260 Injection is a chemotherapy agent indicated for breast, pancreatic, and non-small cell lung cancers. Administered intravenously by a healthcare professional, the dosage and frequency are determined by your physician based on your condition and may vary. Strict adherence to your doctor's prescription is crucial; incorrect usage or overdosage can lead to severe adverse reactions. Therapeutic effects may not be apparent for weeks or months; discontinue only under medical supervision. Common side effects include nausea, vomiting, and fatigue. Serious side effects such as edema (hand and lip swelling), alopecia, and weight increase are also possible. Your physician may prescribe supplementary medications to mitigate these effects. Report unexplained bleeding or bruising, sore throat, mouth sores, or fever immediately. This medication can suppress blood cell production (red and white blood cells), increasing infection risk. Regular blood tests monitoring blood counts and liver function are mandatory. Prior to commencing treatment, disclose any existing heart, liver, or kidney conditions, and all medications, including antibiotics, to your doctor. Drug interactions are possible; a comprehensive medication review is essential. This medication is contraindicated during pregnancy and lactation. Reliable contraception is essential for both partners throughout the treatment period to prevent conception.
Uses of Jupipac 260 Injection
Cancers of the breast, lung (non-small cell type), and pancreas
Major Benefits of Jupipac 260 Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Jupipac 260 Injection:
- Nausea
- Vomiting
- Weakness
- Low blood platelets
- Rash
- Upper respiratory tract infection
- Urinary tract infection
- Bleeding
- Anemia (low number of red blood cells)
- Flushing (sense of warmth in the face, ears, neck and trunk)
- Hair loss
- Decreased blood pressure
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Diarrhea
- Decreased white blood cell count (neutrophils)
How to use Jupipac 260 Injection:
This medication will be administered by your healthcare provider; please do not attempt self-medication.
How Jupipac 260 Injection works:
Jupipac 260 Injection is a cancer treatment that disrupts microtubule function, essential for cancer cell division and proliferation. This disruption inhibits cancer growth and leads to cell death.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while using Jupipac 260 Injection is contraindicated.
PregnancyCONSULT YOUR DOCTOR
Administering Jupipac 260 Injection during pregnancy is contraindicated due to established risks to the fetus. Exceptions may exist in critical circumstances where a physician deems the potential benefits outweigh the hazards. Physician consultation is essential.
Breast feedingUNSAFE
Administering Jupipac 260 Injection while breastfeeding is contraindicated. Evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Administering Jupipac 260 Injection might induce adverse reactions potentially impairing driving capabilities. While continued driving between treatment cycles isn't prohibited, the medication's alcohol content warrants caution regarding driving safety.
KidneySAFE IF PRESCRIBED
Jupipac 260 Injection poses no safety concerns for individuals with kidney impairment; dose modification isn't necessary. Nevertheless, consultation with a physician is advisable if you have pre-existing kidney conditions.
LiverCAUTION
Patients with liver impairment should use Jupipac 260 Injection cautiously, potentially requiring a modified dosage. Physician consultation is advised. Jupipac 260 Injection is contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Jupipac 260 Injection :
NA
Facts to Know About Jupipac 260 Injection
| Label | Value |
|---|---|
| Chemical Category | Taxane-Based Drugs |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Active Class | Taxanes: Antimicrotubule Agents |
3,018 People bought this recently